The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders

J Clin Med. 2023 Apr 14;12(8):2865. doi: 10.3390/jcm12082865.

Abstract

The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a critical role in orchestrating immune and inflammatory responses, and it is essential for a wide range of cellular processes, including differentiation, cell growth, and apoptosis. Over the years, this pathway has been heavily investigated due to its key role in the pathogeneses of several chronic inflammatory conditions, e.g., psoriasis, atopic dermatitis (AD), and inflammatory bowel diseases (IBDs). Nevertheless, the impact of this pathway on the pathogenesis of inflammatory conditions remains unclear. This review describes the role of the JAK/STAT signaling pathway in the pathogenesis of inflammatory diseases such as psoriasis (Pso), psoriatic arthritis (PsA), AD, and IBD with a focus on ulcerative colitis (UC) and briefly resumes the use of JAK inhibitors in their clinical management.

Keywords: JAK-STAT inhibitors; JAK/STAT signaling pathway; atopic dermatitis; inflammatory bowel diseases; inflammatory disorders; psoriasis; psoriatic arthritis.

Publication types

  • Review

Grants and funding

This research received no external funding.